Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States

Borer, Jeffrey S.; Kansal, Anuraag R.; Dorman, Emily; Krotneva, Stanimira; Zheng, Ying; Patel, Hitendra; Tavazzi, Luigi; Komajda, Michel; Ford, Ian; Böhm, Michael; Kielhorn, A

doi:10.18553/jmcp.2016.22.9.1064

Cited by 2 publications

(1 citation statement)

References 14 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first budget impact analysis that was conducted specifically in US patients with HFrEF following a WHFE. In addition, prior studies in HFrEF were conducted among patients with slightly different patient profile and clinical characteristics (e.g., New York Heart Association classification II–IV, LVEF of lower than 40%) [ 30 – 32 ]. Although this study indicates limited budget impact for vericiguat, further cost-effectiveness analysis is warranted to provide a comprehensive assessment of the long-term clinical and economic implications of adding vericiguat to a commercial health plan in the US healthcare system.…”

Section: Discussionmentioning

confidence: 99%

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event

et al. 2021

View full text Add to dashboard Cite

Introduction In the USA, patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) following a worsening HF event (WHFE) have significantly increased healthcare resource use and medical costs. This analysis aimed to estimate the budget impact of vericiguat as an add-on therapy to guideline-directed medical therapy (GDMT) for the treatment of chronic HFrEF following a WHFE from a US commercial payer perspective. Methods A model was developed to estimate the budget impact of adding vericiguat to the formulary by comparing a current scenario (GDMT) and a new scenario (vericiguat plus GDMT) to a hypothetical 10-million-member commercial payer over a 3-year time horizon. Epidemiology data was obtained from literature. Treatment utilization rates of GDMT and clinical inputs (HF hospitalization and cardiovascular [CV] morality) were based on the VICTORIA trial in which patients with chronic HFrEF following a WHFE were randomized to GDMT plus placebo or GDMT plus vericiguat. Costs (2020 US$) included drug acquisition, hospitalization, routine care, and mortality. Results Approximately 20,510 prevalent cases in year 1 and 3109 annual incident cases in subsequent years were estimated to be eligible for treatment with vericiguat. At a utilization rate of 5%, 10%, and 15% for vericiguat over years 1–3, the per member per month (PMPM) budget impact was estimated to be $0.048, $0.064, and $0.086, respectively, associated with 44, 32, and 30 fewer HF hospitalizations and 7, 12, and 18 fewer CV deaths, respectively. Reduction in HF hospitalizations and CV deaths reduced the budget impact by 14% in total over 3 years. Conclusion Adding vericiguat to commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HF hospitalizations and CV deaths. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01681-2.

show abstract

Section: Discussionmentioning

confidence: 99%